List of works - Marc Ladanyi

The landscape of somatic copy-number alteration across human cancers

scientific article

Somatic mutations affect key pathways in lung adenocarcinoma

scientific article

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

scientific article published on July 1, 2012

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

scientific article

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

scientific article

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

scientific article

Characterizing the cancer genome in lung adenocarcinoma

scientific article

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

scientific article

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

scientific article

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

scientific article

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

scientific article published on 20 March 2015

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

scientific article

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

scientific article

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

scientific article published in February 2006

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

scientific article published on 5 September 2012

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

scientific article

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

scientific article

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis

scientific article

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

scientific article

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

scientific article published on April 11, 2011

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

scientific article

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

scientific article

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

scientific article

Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis

scientific article

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

scientific article published on 16 January 2018

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

scientific article published on March 26, 2013

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

scientific article published on 29 November 2009

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

scientific article published on May 31, 2013

Advances in sarcoma genomics and new therapeutic targets

scientific article

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

article

Pattern discovery and cancer gene identification in integrated cancer genomic data

scientific article

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

scientific article

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

scientific article published on January 6, 2012

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

article

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

scientific article published on May 2008

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

scientific article

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

scientific article published in August 2005

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

scientific article

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

scientific article

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

scientific article published on 20 July 2009

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

scientific article published on August 2007

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

scientific article

Genetic predictors of MEK dependence in non-small cell lung cancer

scientific article

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

scientific journal article

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

scientific article

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

scientific article published on August 2005

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

scientific article published on November 1, 2011

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

scientific article

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

scientific article

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases

scientific article

List of works by Marc Ladanyi

The landscape of somatic copy-number alteration across human cancers

Somatic mutations affect key pathways in lung adenocarcinoma

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Characterizing the cancer genome in lung adenocarcinoma

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Advances in sarcoma genomics and new therapeutic targets

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Pattern discovery and cancer gene identification in integrated cancer genomic data

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

Genetic predictors of MEK dependence in non-small cell lung cancer

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases